Literature DB >> 23185024

Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.

Parameshwaran Ramanan1, Megan R Edwards, Reed S Shabman, Daisy W Leung, Ariel C Endlich-Frazier, Dominika M Borek, Zbyszek Otwinowski, Gai Liu, Juyoung Huh, Christopher F Basler, Gaya K Amarasinghe.   

Abstract

Filoviruses, marburgvirus (MARV) and ebolavirus (EBOV), are causative agents of highly lethal hemorrhagic fever in humans. MARV and EBOV share a common genome organization but show important differences in replication complex formation, cell entry, host tropism, transcriptional regulation, and immune evasion. Multifunctional filoviral viral protein (VP) 35 proteins inhibit innate immune responses. Recent studies suggest double-stranded (ds)RNA sequestration is a potential mechanism that allows EBOV VP35 to antagonize retinoic-acid inducible gene-I (RIG-I) like receptors (RLRs) that are activated by viral pathogen-associated molecular patterns (PAMPs), such as double-strandedness and dsRNA blunt ends. Here, we show that MARV VP35 can inhibit IFN production at multiple steps in the signaling pathways downstream of RLRs. The crystal structure of MARV VP35 IID in complex with 18-bp dsRNA reveals that despite the similar protein fold as EBOV VP35 IID, MARV VP35 IID interacts with the dsRNA backbone and not with blunt ends. Functional studies show that MARV VP35 can inhibit dsRNA-dependent RLR activation and interferon (IFN) regulatory factor 3 (IRF3) phosphorylation by IFN kinases TRAF family member-associated NFkb activator (TANK) binding kinase-1 (TBK-1) and IFN kB kinase e (IKKe) in cell-based studies. We also show that MARV VP35 can only inhibit RIG-I and melanoma differentiation associated gene 5 (MDA5) activation by double strandedness of RNA PAMPs (coating backbone) but is unable to inhibit activation of RLRs by dsRNA blunt ends (end capping). In contrast, EBOV VP35 can inhibit activation by both PAMPs. Insights on differential PAMP recognition and inhibition of IFN induction by a similar filoviral VP35 fold, as shown here, reveal the structural and functional plasticity of a highly conserved virulence factor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23185024      PMCID: PMC3528546          DOI: 10.1073/pnas.1213559109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.

Authors:  Christopher R Kimberlin; Zachary A Bornholdt; Sheng Li; Virgil L Woods; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

2.  Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain.

Authors:  Michael Schümann; Thorsten Gantke; Elke Mühlberger
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

3.  Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling.

Authors:  Mathieu Mateo; St Patrick Reid; Lawrence W Leung; Christopher F Basler; Viktor E Volchkov
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

4.  RIG-I activation inhibits ebolavirus replication.

Authors:  Christina F Spiropoulou; Priya Ranjan; Melissa B Pearce; Tara K Sealy; César G Albariño; Shivaprakash Gangappa; Takashi Fujita; Pierre E Rollin; Stuart T Nichol; Thomas G Ksiazek; Suryaprakash Sambhara
Journal:  Virology       Date:  2009-07-23       Impact factor: 3.616

Review 5.  Evasion of interferon responses by Ebola and Marburg viruses.

Authors:  Christopher F Basler; Gaya K Amarasinghe
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

6.  Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus.

Authors:  Martin Schlee; Andreas Roth; Veit Hornung; Cristina Amparo Hagmann; Vera Wimmenauer; Winfried Barchet; Christoph Coch; Markus Janke; Aleksandra Mihailovic; Greg Wardle; Stefan Juranek; Hiroki Kato; Taro Kawai; Hendrik Poeck; Katherine A Fitzgerald; Osamu Takeuchi; Shizuo Akira; Thomas Tuschl; Eicke Latz; Janos Ludwig; Gunther Hartmann
Journal:  Immunity       Date:  2009-07-02       Impact factor: 31.745

7.  The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus.

Authors:  Sven Enterlein; Kristina M Schmidt; Michael Schümann; Dominik Conrad; Verena Krähling; Judith Olejnik; Elke Mühlberger
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

8.  Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.

Authors:  Amy L Hartman; Brian H Bird; Jonathan S Towner; Zoi-Anna Antoniadou; Sherif R Zaki; Stuart T Nichol
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

9.  Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1.

Authors:  Kathleen C Prins; Washington B Cárdenas; Christopher F Basler
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

10.  Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes.

Authors:  Anthony Sanchez; Kent E Wagoner; Pierre E Rollin
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

View more
  55 in total

1.  Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Authors:  Megan R Edwards; Gai Liu; Chad E Mire; Suhas Sureshchandra; Priya Luthra; Benjamin Yen; Reed S Shabman; Daisy W Leung; Ilhem Messaoudi; Thomas W Geisbert; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

2.  Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism.

Authors:  Shridhar Bale; Jean-Philippe Julien; Zachary A Bornholdt; Alexander S Krois; Ian A Wilson; Erica Ollmann Saphire
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

Review 3.  Extracellular RNA Sensing by Pattern Recognition Receptors.

Authors:  Megumi Tatematsu; Kenji Funami; Tsukasa Seya; Misako Matsumoto
Journal:  J Innate Immun       Date:  2018-11-07       Impact factor: 7.349

Review 4.  Ebola virus disease.

Authors:  Nicholas J Beeching; Manuel Fenech; Catherine F Houlihan
Journal:  BMJ       Date:  2014-12-10

Review 5.  Innate immune evasion by filoviruses.

Authors:  Christopher F Basler
Journal:  Virology       Date:  2015-04-03       Impact factor: 3.616

6.  Structural Insight into Nucleoprotein Conformation Change Chaperoned by VP35 Peptide in Marburg Virus.

Authors:  Baocheng Liu; Shishang Dong; Guobang Li; Wenming Wang; Xiang Liu; Yantong Wang; Cheng Yang; Zihe Rao; Yu Guo
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

7.  Ebola Virus Produces Discrete Small Noncoding RNAs Independently of the Host MicroRNA Pathway Which Lack RNA Interference Activity in Bat and Human Cells.

Authors:  Abhishek N Prasad; Adam J Ronk; Steven G Widen; Thomas G Wood; Christopher F Basler; Alexander Bukreyev
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

8.  Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription.

Authors:  Andrey Ivanov; Palaniappan Ramanathan; Christian Parry; Philipp A Ilinykh; Xionghao Lin; Michael Petukhov; Yuri Obukhov; Tatiana Ammosova; Gaya K Amarasinghe; Alexander Bukreyev; Sergei Nekhai
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

9.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

10.  The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Authors:  Ndongala M Lubaki; Philipp Ilinykh; Colette Pietzsch; Bersabeh Tigabu; Alexander N Freiberg; Richard A Koup; Alexander Bukreyev
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.